EXHIBIT





DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration Rockville, MD 20857

IND 64,915

Myogen, Inc.

Attention: Mr. J. William Freytag 7575 West 103rd Avenue, Suite #102

Westminster, CO 80021

Dear Mr. Freytag:

We acknowledge receipt of your Investigational New Drug Application (IND) submitted under section 505(i) of the Federal Food, Drug, and Cosmetic Act. Please note the following identifying data:

IND Number Assigned: 64,915

Sponsor:

Myogen, Inc.

Name of Drug:

BSF 208075

Date of Submission: June 3, 2002

Date of Receipt: June 4, 2002

Studies in humans may not be initiated until 30 days after the date of receipt shown above. If, on or before July 3, 2002, we identify deficiencies in the IND that require correction before human studies begin or that require restriction of human studies, we will notify you immediately that (1) clinical studies may not be initiated under this IND ("clinical hold") or that (2) certain restrictions apply to clinical studies under this IND ("partial clinical hold"). In the event of such notification, you must not initiate or you must restrict such studies until you have submitted information to correct the deficiencies, and we have notified you that the information you submitted is satisfactory.

It has not been our policy to object to a sponsor, upon receipt of this acknowledgement letter, either obtaining supplies of the investigational drug or shipping it to investigators listed in the IND. However, if the drug is shipped to investigators, they should be reminded that studies may not begin under the IND until 30 days after the IND receipt date or later if the IND is placed on clinical hold.

As sponsor of this IND, you are responsible for compliance with the Federal Food, Drug, and Cosmetic Act and the implementing regulations (Title 21 of the Code of Federal Regulations). Those responsibilities include (1) reporting any unexpected fatal or life-threatening adverse experience associated with use of the drug by telephone or fax no later than 7 calendar days after initial receipt of the information [21 CFR 312.32(c)(2)]; (2) reporting any adverse experience associated with use of the drug that is both serious and unexpected in writing no later than 15 calendar days after initial receipt of the information.[21 CFR 312.32(c)(1)]; and (3) submitting annual progress reports [21 CFR 312.33].

IND 64,915 Page 2

Please forward all future communications concerning this IND in triplicate, identified by the above IND number, to either of the following addresses:

U.S. Postal Service:

Center for Drug Evaluation and Research Division of Cardio-Renal Drug Products, HFD-110 Attention: Division Document Room 5600 Fishers Lane Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room
1451 Rockville Pike
Rockville, Maryland 20852

If you have any questions, please call me at (301) 594-5333.

Sincerely yours,

Zelda McDonald
Regulatory Project Manager
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

cc:

Quintiles, Inc. Cynthia Kirk, Ph.D., RAC P.O. Box 9708 (Dock 6, F3-M3026) Kansas City, MO 64134-0708 This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Zelda McDonald 6/10/02 02:21:20 PM